Resources

Filter:

Read more

Newsweek World's Best Digital Health Companies 2024

April 2024

Publication: Press Release

Newsweek Selects Caristo Diagnostics as One of World’s Best Digital Health Companies

Caristo Diagnostics, a leading cardiac disease diagnostics company, has been named by Newsweek as one of World’s Best Digital Health…

Read more

April 2024

Publication: Press Release

Surrey Cardiovascular Clinic and Caristo Diagnostics Launch Employee Heart Wellness and Disease Prevention Program for UK Employers

Caristo’s AI technology predicts heart attack risk for employee wellness initiative from respected centre of excellence OXFORD, England and SURREY, England , April 23,…

Read more

Caristo and Abcentra Collaboration

April 2024

Publication: Press Release

American College of Cardiology Presentation Highlights Promising Results Showing Potential to Reduce Coronary Inflammation with Abcentra’s Orticumab

Caristo’s CaRi-Heart® AI Technology used to monitor effects of Orticumab detected a reduction in coronary inflammation and predicted a 50%…

Read more

Quote by Dr Jonathan Rodrigues, Heart & Lung Health

March 2024

Publication: Press Release

Heart & Lung Health selects Caristo Diagnostics AI technology to provide early diagnosis of coronary artery disease UK-wide

UK-wide radiologist network to deploy Caristo’s pioneering CaRi-Heart® solution  Oxford, March 19, 2024— Heart & Lung Health (HLH), a UK-wide network of…

Read more

March 2024

Publication: Blog

Caristo’s CaRi-Heart® technology addresses the gender gap in understanding cardiovascular disease risk in women

Cardiovascular risk prediction models based on traditional risk factors underestimate risk in women – review article by European Atherosclerosis Society…

Read more

Agepha Pharma partners with Caristo Diagnostics

January 2024

Publication: Press Release

Agepha Pharma and Caristo Diagnostics Team Up to Fight Coronary Inflammation

Press Release Agepha Pharma, a leading multinational pharmaceutical company with the first FDA-approved anti-inflammatory cardiovascular treatment (LODOCO®– colchicine, 0.5 mg…

Read more

AHA Late Breaking Science Presentation

November 2023

Publication: Press Release

American Heart Association Late-Breaking Science Presentation Reveals Majority of Adverse Cardiac Events Occur Among Patients Without Obstructive Coronary Artery Disease but Risks Are Detectable by Novel AI

Press Release Caristo’s AI Technology for Coronary Inflammation Measurement and Risk Assessment Can Transform Risk Stratification and Management of Patients…

Read more

Perivascular adipose tissue (PVAT) as a source of imaging biomarkers and a therapeutic target. FAI, fat attenuation index.

October 2023

Publication: European Heart Journal, August 2023

Perivascular adipose tissue as a source of therapeutic targets and clinical biomarkers: A clinical consensus statement from the European Society of Cardiology Working Group on Coronary Pathophysiology and Micro-circulation

This clinical consensus statement from the European Society of Cardiology defines perivascular adipose tissue (PVAT) and highlights the biological mechanisms…

Next
View Resources Archive

Get in touch for more information.

  • Registered in England and Wales under company number 11429590
  • CaRi-Heart® is limited to investigational use in the United States.

All contents of this website are copyright 2018 - 2021 Caristo Diagnostics Ltd. All rights reserved. No content may be copied or reproduced without the express permission of Caristo Diagnostics Ltd.
All copyright, trade-marks, design rights, database rights, patents and other intellectual property rights (registered and unregistered) in and on this website are owned by Caristo Diagnostics Ltd. and/or certain third parties.